<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Arnold S Freedman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jon C Aster, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Lister, MD, FRCP, FRCPath, FRCR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peripheral T cell lymphomas (PTCLs) comprise a heterogeneous group of generally aggressive neoplasms of T cell origin that manifest as lymphadenopathy or extranodal involvement. Although PTCL includes multiple subtypes that are distinguished by clinical, pathologic, or genetic features, together they account for &lt;15 percent of all non-Hodgkin lymphomas (NHL) in adults.
        </p>
        <p>
         PTCL nosology is evolving as the underlying pathobiology and genetic features are better defined. PTCLs should be diagnosed and classified according to World Health Organization (WHO) 5
         <sup>
          th
         </sup>
         edition [
         <a href="#rid1">
          1
         </a>
         ] or the International Consensus Classification of Mature Lymphoid Neoplasms (ICC) [
         <a href="#rid2">
          2
         </a>
         ], rather than earlier nosologic systems.
        </p>
        <p>
         PTCL, not otherwise specified (NOS), is a heterogeneous group of predominantly nodal T cell lymphomas for which no consistent immunophenotypic, genetic, or clinical features have been defined. This category likely represents a conglomerate of multiple, as-yet-undefined PTCL subtypes. They were previously classified as "diffuse small cleaved, mixed, large cell and immunoblastic T cell lymphomas" in the Working Formulation [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         At present, PTCL, NOS is a diagnosis of exclusion for mature T cell NHLs that do not meet criteria for other defined subtypes of PTCL. Among PTCLs, the most common subtypes in decreasing frequency of diagnosis are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PTCL, NOS
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anaplastic large cell lymphoma, primary systemic type
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T follicular helper (Tfh) cell lymphoma, which includes angioimmunoblastic T cell lymphoma and related neoplasms
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extranodal NK/T cell lymphoma, nasal type
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subcutaneous panniculitis-like T cell lymphoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enteropathy associated T cell lymphoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monomorphic epitheliotropic intestinal T cell lymphoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatosplenic T cell lymphoma
        </p>
        <p>
        </p>
        <p>
         The clinical presentation, pathologic features, and diagnosis of PTCL, NOS are discussed here. Management of PTCLs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4749.html" rel="external">
          "Initial treatment of peripheral T cell lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peripheral T cell lymphomas (PTCL), not otherwise specified (NOS), is the most common subtype of PTCL in Western countries, accounting for approximately 30 percent of PTCLs and 4 percent of non-Hodgkin lymphomas (NHLs) overall [
         <a href="#rid3">
          3,5-8
         </a>
         ]. The incidence of PTCL, NOS increased in the United States from approximately 0.1 cases per 100,000 population in 1992 to 0.4 cases per 100,000 population in 2006 [
         <a href="#rid9">
          9
         </a>
         ]. This increase may reflect increased awareness and improved diagnostic methods. The incidence is higher in Asia, where PTCLs account for 15 to 20 percent of all NHLs; approximately 20 to 25 percent of those cases are classified as PTCL, NOS [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Most patients are adults; median age at diagnosis is 60 years [
         <a href="#rid10">
          10
         </a>
         ]. The diagnosis is more common in men than women by a ratio of approximately 2:1 [
         <a href="#rid11">
          11
         </a>
         ]. In the US, the incidence is highest in individuals of African descent, it is lower among White people (both Hispanic individuals and non-Hispanic individuals) and individuals of Asian/Pacific Island descent, and it is lowest among American Indian/Alaskan native people [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with PTCL, NOS present with generalized lymphadenopathy, with or without extranodal disease [
         <a href="#rid10">
          10,11,13
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – An international database of 340 cases of PTCL, NOS reported that 38 percent of patients had nodal disease alone, 49 percent had nodal plus extranodal disease, and 13 percent had extranodal disease without nodal involvement [
         <a href="#rid11">
          11
         </a>
         ]. Hepatomegaly and splenomegaly were seen in 17 and 24 percent of patients, respectively, and bone marrow was involved in 20 percent of cases. Systemic B symptoms (fever, night sweats, weight loss) were reported in one-third of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In that study, disease stage I, II, III, and IV accounted for 14, 17, 26, and 43 percent of cases, respectively [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extranodal involvement
         </strong>
         – Skin and gastrointestinal tract are the most common sites of extranodal disease [
         <a href="#rid5">
          5,14-16
         </a>
         ]. Less frequently, lung, salivary gland, and central nervous system are involved. Half of cases display elevated serum lactate dehydrogenase (LDH) and 14 percent had hypergammaglobulinemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While circulating lymphoma cells may be seen, leukemic presentations are rare [
         <a href="#rid5">
          5
         </a>
         ]. Some cases are associated with eosinophilia, pruritus, and/or hemophagocytosis  (
         <a class="graphic graphic_picture graphicRef52783" href="/z/d/graphic/52783.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. Thrombocytopenia and anemia are seen in one-quarter of patients [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PTCL, NOS is a heterogeneous group of tumors of T cell origin that exhibit varying histology.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymph nodes usually demonstrate effacement of the normal architecture by sheets of atypical lymphoid cells in a paracortical or diffuse pattern  (
         <a class="graphic graphic_picture graphicRef83591" href="/z/d/graphic/83591.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytomorphology
         </strong>
         – Tumor cells of PTCL, NOS have no characteristic morphologic features and typically include variable mixtures of small, intermediate, and large atypical cells [
         <a href="#rid18">
          18,19
         </a>
         ]. The cells contain pleomorphic, irregular, vesicular, or hyperchromatic nuclei with prominent nucleoli and usually exhibit a high mitotic rate [
         <a href="#rid5">
          5
         </a>
         ]. They sometimes have clear cytoplasm, a morphologic feature suggestive of a T cell phenotype.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patterns of involvement
         </strong>
         – The malignant cells of PTCL are typically admixed with variable numbers of eosinophils, plasma cells, resting or activated B cells, and epithelioid histiocytes (activated macrophages).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Involved extranodal tissues demonstrate a diffuse infiltrate of atypical lymphoid cells. Skin involvement commonly takes the form of infiltrates in the dermis and subcutis and can result in nodules with central ulceration [
         <a href="#rid20">
          20
         </a>
         ]. Splenic involvement can vary from solitary fleshy nodules to diffuse involvement of the white or red pulp [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lymphoepithelioid cell lymphoma (Lennert's lymphoma) was previously applied as a label to cases rich in epithelioid histiocytes  (
         <a class="graphic graphic_picture graphicRef83592" href="/z/d/graphic/83592.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid21">
          21
         </a>
         ], which are now considered a variant of PTCL, NOS. The so-called "T-zone" variant is characterized by growth in a paracortical pattern, often surrounding reactive B cell follicles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         PTCLs with malignant T cells growing as aggregates within lymphoid follicles were previously classified as a "follicular" variant of PTCL, NOS. However, most T cell lymphomas with follicular growth patterns express markers of Tfh cells and are now classified as variants of T follicular helper (Tfh) cell lymphoma in the World Health Organization (WHO) Classification of Hematolymphoid Tumors, 5
         <sup>
          th
         </sup>
         Edition (WHO5) [
         <a href="#rid1">
          1
         </a>
         ] and the International Consensus Classification (ICC) of Lymphoid Neoplasms [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Immunophenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no characteristic immunophenotype for PTCL, NOS. T cell antigens are expressed variably, and tumors are generally negative for B cell antigens. Some tumors may express both T cell and B cell antigens, which can lead to diagnostic challenges.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          T cell antigens
         </strong>
         – PTCL, NOS is usually characterized by an aberrant T cell phenotype.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In most cases, one or more mature T cell antigens are lost, while expression of CD4 and CD8 varies [
         <a href="#rid22">
          22
         </a>
         ]. CD3, CD2, CD5, and CD7 are expressed variably, but CD5 and CD7 are frequently downregulated. A CD4-positive/CD8-negative immunophenotype is most common in nodal cases. Most cases express alpha/beta T cell receptors, which facilitates the distinction from gamma-delta T cell lymphomas and NK cell lymphomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other antigens
         </strong>
         – These tumors are generally negative for B cell antigens, but rare tumors may express CD20 [
         <a href="#rid19">
          19,23,24
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CD15 may be positive and, rarely, may be co-expressed with CD30 [
         <a href="#rid25">
          25
         </a>
         ], leading to possible confusion with classic Hodgkin lymphoma. CD15 expression is associated with an adverse prognosis [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Genetic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nearly all cases demonstrate cytogenetic abnormalities, but none is specific for PTCL, NOS. Clonal T cell receptor (
         <em>
          TCR
         </em>
         ) gene rearrangements are usually detected, while immunoglobulin genes are germline.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chromosomal abnormalities
         </strong>
         – Although 90 percent of PTCLs demonstrate cytogenetic abnormalities, none is specific for PTCL, NOS [
         <a href="#rid26">
          26-31
         </a>
         ]. The most common chromosomal translocations in PTCL, NOS are t(7;14), t(11;14), inv(14), and t(14;14) [
         <a href="#rid32">
          32
         </a>
         ]. Many tumors demonstrate chromosomal gains in 7q, 8q, 17q, and 22q, and chromosomal losses in 4q, 5q, 6q, 9p, 10q, 12q, and 13q [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular events
         </strong>
         – Clonal T cell receptor (
         <em>
          TCR
         </em>
         ) gene rearrangements are usually (but not always) detected, while immunoglobulin genes are germline [
         <a href="#rid33">
          33,34
         </a>
         ]. Structural abnormalities involving tumor suppressor genes are much more frequent than aberrations of oncogenes, which are rare [
         <a href="#rid35">
          35-38
         </a>
         ]. Efforts are underway to apply genomic profiling and other techniques to further classify this heterogeneous group of tumors [
         <a href="#rid35">
          35-38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           TCR
          </em>
         </strong>
         <strong>
          -related rearrangements
         </strong>
         – The following gene loci are most often involved in chromosomal translocations in PTCL, NOS:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         14q11 (TCR alpha/delta [
         <em>
          TRA/TRD
         </em>
         ])
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         7q34-35 (TCR beta [
         <em>
          TRB
         </em>
         ])
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         7p15 (TCR gamma [
         <em>
          TRG
         </em>
         ])
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Less often,
         <em>
          TRD
         </em>
         (TCR delta)
         <em>
         </em>
         can be rearranged with
         <em>
          IRF4
         </em>
         on chromosome 6p25, leading to overexpressi
         <em>
          on of IRF4
         </em>
         (also kno
         <em>
          wn as MUM1
         </em>
         ) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Analogous to B cell lymphomas where immunoglobulin (Ig) loci are affected, chromosomal translocations in PTCL typically involve
         <em>
          TCR
         </em>
         genes. However, translocations involving
         <em>
          TCR
         </em>
         genes in PTCLs are much less frequent than translocations involving the Ig genes in B cell lymphomas. This is likely because, while mature B cells continue to diversify their Ig genes in germinal centers through somatic hypermutation and class switching (events that are prone to errors and can result in translocations),
         <em>
          TCR
         </em>
         genes of mature T cells are genomically stable and presumably less likely to participate in oncogenic rearrangements.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tumor suppressors
         </strong>
         – The tumor suppressor genes
         <em>
          CDKN2A, PTEN,
         </em>
         and
         <em>
          TP53
         </em>
         are most often affected. A study that included 63 cases of PTCL, NOS, reported
         <em>
          CDKN2A
         </em>
         deletion in 46 percent,
         <em>
          PTEN
         </em>
         deletion in 26 percent, and co-deletion of
         <em>
          CDKN2A
         </em>
         and
         <em>
          PTEN
         </em>
         (an aberration that appears to be highly specific for PTCL, NOS) in 13 percent of cases [
         <a href="#rid40">
          40
         </a>
         ]. Structural abnormalities involving
         <em>
          TP63
         </em>
         are also found [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gene expression profiles (GEPs) of PTCL, NOS are clearly distinct from resting normal T cells and are most closely related to activated CD4-positive or CD8-positive peripheral T cells [
         <a href="#rid41">
          41
         </a>
         ]. Two subgroups of PTCL, NOS, with distinct gene expression profiles have been described. These two profiles are driven by the TBX-21 or GATA-3 transcription factors, which normally play a role in the differentiation of CD4-positive T cells into Th1 and Th2 helper cells, respectively [
         <a href="#rid42">
          42-44
         </a>
         ]. Other distinctive GEPs have been described with PTCL, NOS, angioimmunoblastic T cell lymphoma, and anaplastic large cell lymphoma [
         <a href="#rid41">
          41,44-46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         PTCL, NOS and other lymphomas may be suspected in individuals with lymphadenopathy, splenomegaly, constitutional symptoms, and findings related to organ infiltration.
        </p>
        <p class="headingAnchor" id="H3685071052">
         <span class="h2">
          Biopsy specimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of PTCL, NOS requires an adequate biopsy specimen. An excisional lymph node biopsy or a substantial incisional specimen of a node or other tissue biopsy should be obtained whenever possible. Thin needle biopsies are difficult to interpret, as architectural effacement cannot be assessed, and the typical mixed cell infiltrate can mimic a reactive process. (See
         <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">
          "Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Type of biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2031746247">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         PTCL, NOS is a diagnosis of exclusion. This heterogeneous category comprises predominantly nodal T cell lymphomas for which no consistent immunophenotypic, genetic, or clinical features have been defined. PTCL nosology is evolving as their pathobiology and molecular features are better defined. PTCLs should be diagnosed and classified according to World Health Organization (WHO) 5
         <sup>
          th
         </sup>
         edition [
         <a href="#rid1">
          1
         </a>
         ] or the International Consensus Classification of Mature Lymphoid Neoplasms (ICC) [
         <a href="#rid2">
          2
         </a>
         ], rather than earlier nosologic systems.
        </p>
        <p>
         Diagnosis of PTCL, NOS requires morphologic and immunophenotypic evidence for a T cell lymphoma that does not meet criteria for other PTCL subtypes  (
         <a class="graphic graphic_table graphicRef55385" href="/z/d/graphic/55385.html" rel="external">
          table 1
         </a>
         ). Diagnosis does not require documentation of genetic features, except to exclude other conditions. While most cases have cytogenetic abnormalities, the findings are heterogeneous, and no finding is specific for these disorders [
         <a href="#rid47">
          47,48
         </a>
         ]. Assignment to a genetic subgroup of PTCL, NOS is not routinely incorporated into clinical diagnosis.
        </p>
        <p>
         Because PTCL, NOS is a diagnosis of exclusion and it is a heterogeneous category of diseases, diagnostic agreement rate among expert hematopathologists is only 75 percent [
         <a href="#rid11">
          11
         </a>
         ]. As with other T cell lymphomas, knowledge of pertinent clinical and laboratory findings improves diagnostic accuracy.
        </p>
        <p class="headingAnchor" id="H4223528857">
         <span class="h3">
          Morphology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histologic examination of the biopsy material usually demonstrates variable mixtures of atypical small, intermediate, and large lymphoid cells. The tumor cells usually contain pleomorphic, irregular, vesicular, or hyperchromatic nuclei with prominent nucleoli and a high mitotic rate. In some cases, the neoplastic cells have clear cytoplasm, a morphologic feature that is suggestive of a T cell phenotype. (See
         <a class="local">
          'Histology'
         </a>
         above.)
        </p>
        <p>
         The malignant cells of PTCL are typically admixed with varying numbers of eosinophils, plasma cells, resting or activated B cells, and epithelioid histiocytes (activated macrophages).
        </p>
        <p class="headingAnchor" id="H585898195">
         <span class="h3">
          Immunophenotypic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The immunophenotype of PTCL, NOS varies widely, but it must confirm the T cell origin of the tumor. Immunohistochemistry is more reliable than flow cytometry for establishing the immunophenotype, because large lymphoid cells are sometimes lost or disrupted during tissue processing for flow cytometry.
        </p>
        <p>
         PTCL, NOS always demonstrates expression of at least one pan-T antigen (ie, CD2, CD3, CD5, CD7). Approximately half of cases have an aberrant immunophenotype, defined by the loss of a pan-T cell antigen (most often CD5 or CD7) that is expressed by most normal mature T cells [
         <a href="#rid49">
          49,50
         </a>
         ]. Detection of surface CD3 (best assessed by flow cytometry) can also be helpful to exclude rare lymphomas of natural killer (NK) cell origin.
        </p>
        <p>
         In difficult or equivocal cases, detection of a clonal T cell receptor (
         <em>
          TCR
         </em>
         ) rearrangement, using a polymerase chain reaction (PCR)-based assay, can help to confirm a T cell origin of the tumor.
        </p>
        <p class="headingAnchor" id="H2788224280">
         <span class="h3">
          Exclude other categories of PTCL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other subtypes of PTCL must be excluded to diagnose PTCL, NOS, including:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anaplastic large cell lymphoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T follicular helper (Tfh) cell lymphoma, which includes angioimmunoblastic T cell lymphoma and related neoplasms
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extranodal NK/T cell lymphoma, nasal type
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subcutaneous panniculitis-like T cell lymphoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enteropathy associated T cell lymphoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monomorphic epitheliotropic intestinal T cell lymphoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatosplenic T cell lymphoma
        </p>
        <p>
        </p>
        <p>
         Two biological variants of PTCL, NOS have been described [
         <a href="#rid51">
          51
         </a>
         ] but neither is currently considered a distinct subtype, according to WHO5 or ICC [
         <a href="#rid1">
          1,2
         </a>
         ]. Gene expression profiling has described PTCL-TBX21 and PTCL-GATA3 according to the transcriptional programs of T-helper-1 (Th1) and T-helper-2 (Th2) cells, respectively [
         <a href="#rid43">
          43
         </a>
         ]. These subgroups may be recognized using an immunohistochemistry-based algorithm of four markers (TBX21, CXCR3, GATA3, CCR4) [
         <a href="#rid43">
          43,51,52
         </a>
         ]. The PTCL-GATA3 subgroup has been associated with a worse outcome in some studies and has greater genomic complexity [
         <a href="#rid44">
          44
         </a>
         ]. The PTCL-TBX21 subgroup is more heterogeneous, has fewer copy number alterations, and more often has mutations in genes regulating DNA methylation; these cases are generally associated with better prognosis, but cases that express cytotoxic molecules in patients with impaired immunity are aggressive PTCL and mostly cluster with the PTCL-TBX21 subgroup [
         <a href="#rid44">
          44,53
         </a>
         ].
        </p>
        <p>
         Diagnosis and classification of various T cell lymphomas is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">
          "Classification of hematopoietic neoplasms", section on 'Mature T cell or NK cell lineage'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of PTCL, NOS includes lymphomas with similar morphologic and/or immunophenotypic features, including T cell lymphomas  (
         <a class="graphic graphic_table graphicRef55385" href="/z/d/graphic/55385.html" rel="external">
          table 1
         </a>
         ), B cell lymphomas, and Hodgkin lymphoma. Certain benign disorders that cause hyperplasia of nodal paracortical T cell zones may also be included in the differential diagnosis.
        </p>
        <p class="headingAnchor" id="H974714227">
         <span class="h2">
          Lymphomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         PTCL, NOS must be distinguished from other lymphomas and excluding other subtypes of PTCL is required to diagnose PTCL, NOS, as described above. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          T follicular helper (Tfh) cell lymphoma, including angioimmunoblastic T cell lymphoma and related neoplasms
         </span>
         <span class="headingEndMark">
          —
         </span>
         These relatively common subtypes of T cell lymphoma typically present with generalized lymphadenopathy and systemic symptoms. Involved lymph nodes demonstrate partial or complete effacement of the normal nodal architecture by a predominantly paracortical infiltrate of atypical lymphoid cells of different sizes, along with inflammatory cells. Expansion of follicular dendritic cell meshworks is characteristic, and some cases have a follicular growth pattern. There is prominent neovascularization with arborizing high endothelial venules and an expansion of follicular dendritic cells that often surround tumor cells with abundant clear cytoplasm. Many cases also show an expansion of Epstein-Barr virus (EBV)-positive B cells in the background.
        </p>
        <p>
         PTCL, NOS is distinguished from Tfh lymphomas by the absence of the characteristic morphologic features and tumor cell immunophenotype of Tfh lymphomas. PTCL, NOS does not usually express CD10, BCL6, PD1, or CXCL13, which are markers expressed by normal T follicular helper cells [
         <a href="#rid5">
          5,54
         </a>
         ]. Tfh cell lymphomas also have a distinctive pattern of mutations in genes such as
         <em>
          DNMT3A, TET2, IDH2,
         </em>
         and
         <em>
          RHOG
         </em>
         [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4727.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Anaplastic large cell lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anaplastic large cell lymphoma (ALCL) is a lymphoma of T cell or null cell type that typically presents with painless lymphadenopathy, with or without systemic symptoms. Histologically, the tumor includes large lymphoma cells with horseshoe-shaped or embryoid nuclei (hallmark cells) and prominent nucleoli. ALCL demonstrates homogeneous, strong expression of CD30 in a membrane- and golgi-associated pattern. T cell antigens are also commonly expressed.
        </p>
        <p>
         Some PTCL, NOS tumors express CD30 in a subset of cells, but not in the diffuse pattern typical of ALCL. Furthermore, ALCL is often positive for epithelial membrane antigen and ALK, the latter due to the presence of
         <em>
          ALK
         </em>
         gene rearrangements, both of which are absent from PTCL, NOS. Although ALK-negative ALCL is considered a distinct entity, it is not always easily distinguished from CD30-positive PTCL, NOS [
         <a href="#rid1">
          1,2
         </a>
         ]. However, some cases of ALK-negative ALCL can be identified by chromosomal abnormalities that rearrange
         <em>
          DUSP22
         </em>
         or
         <em>
          TP63
         </em>
         [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Hodgkin lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both PTCL, NOS and classic Hodgkin lymphoma (cHL) may contain cells that resemble Reed-Sternberg cells in an inflammatory background. Both CD30 and CD15 are typically positive in cHL; PTCL, NOS can express CD30, but these tumors rarely express CD15. PTCL, NOS is differentiated from cHL by the absence of PAX5 (a B cell-specific factor seen in most cases of cHL) and by expression of alpha/beta T cell receptors and other T cell markers. (See
         <a class="medical medical_review" href="/z/d/html/4691.html" rel="external">
          "Hodgkin lymphoma: Epidemiology and risk factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Adult T cell leukemia-lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adult T cell leukemia-lymphoma (ATL) typically presents with generalized lymphadenopathy, hepatosplenomegaly, immunosuppression, hypercalcemia, lytic bone lesions, and/or skin lesions. The malignant cell of origin in ATL is a transformed HTLV-I infected mature helper (CD4-positive) T-lymphocyte. Nodal ATL cannot be reliably distinguished from PTCL, NOS on morphologic or immunophenotypic grounds, but it can be excluded with certainty if HTLV-I studies (generally serology) are negative, particularly in patients from regions where HTLV-1 is endemic [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4697.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          T cell histiocyte rich large B cell lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         T cell histiocyte rich large B cell lymphoma (THRLBCL) is a variant of large B cell lymphoma that can resemble PTCL, NOS. In THRLBCL, the tumor cells are a minor fraction of the total cellularity, which consists mainly of reactive T cells and histiocytes. Distinction from PTCL, NOS is usually not difficult, as the malignant B cells in THRLBCL express pan B cell markers (eg, CD19, CD20, CD22, CD79a), and usually show rearrangements of Ig heavy chains. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'T cell histiocyte-rich large B cell lymphoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3757920369">
         <span class="h2">
          Nonmalignant disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonmalignant disorders that can resemble PTCL, NOS include hypersensitivity reactions and prolonged or robust immune responses to Epstein-Barr virus or other viruses. For all reactive immune processes, care must be taken not to over-interpret a dominant clone within a reactive T cell expansion in small biopsy specimens.
        </p>
        <p>
         <strong>
          Autoimmune lymphoproliferative syndrome (ALPS)
         </strong>
         — ALPS is an inherited disorder usually caused by germline loss-of-function mutations in
         <em>
          FAS
         </em>
         (CD95),
         <em>
          FASLG
         </em>
         (FAS ligand), or
         <em>
          CASP10
         </em>
         (caspase 10), which participate in a signaling pathway that leads to lymphocyte apoptosis. Characteristically, ALPS presents in childhood with lymphadenopathy, organomegaly, and autoimmune cytopenias. Lymph nodes show paracortical expansion by T cells expressing T cell alpha-beta receptors and CD3 and are negative for CD4 and CD8; this is often accompanied by follicular hyperplasia. Variable numbers of the T cells have an immunoblastic appearance. The degree of tissue involvement, the presence of immunoblasts, and the unusual phenotype of the T cell population may raise the suspicion of lymphoma. Features helpful in distinguishing ALPS from PTCL include the early age of onset, lack of lymph node effacement in biopsy specimens, polyclonal T cell expansion, and detection of pathogenic mutations by DNA sequencing. (See
         <a class="medical medical_review" href="/z/d/html/16837.html" rel="external">
          "Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2809202902">
         <span class="h2">
          Kikuchi-Fujimoto lymphadenitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         This is a self-limited reactive condition of uncertain etiology that most often involves the posterior cervical lymph nodes of young adult women. Kikuchi-Fujimoto lymphadenitis has histologic features that may be confused with T cell lymphoma [
         <a href="#rid56">
          56
         </a>
         ]. Involved lymph nodes show patchy areas effaced by an infiltrate of large, activated CD8-positive cytotoxic T cells, associated with necrosis and karyorrhectic debris. Acute inflammatory cells, such as neutrophils, are absent from the lesions, which instead contain histiocytes of macrophage/monocyte lineage with crescentic nuclei. Key to recognition of Kikuchi-Fujimoto lymphadenitis is the clinical presentation (typically in posterior cervical lymph nodes of young adult women), the circumscribed and non-expansile nature of the nodal infiltrate, and detection of admixed CD123-positive plasmacytoid dendritic cells and histiocytes that express myeloperoxidase. (See
         <a class="medical medical_review" href="/z/d/html/5507.html" rel="external">
          "Kikuchi disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Paracortical hyperplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some cases of PTCL, NOS demonstrate a perifollicular (T-zone) growth pattern similar to that seen in benign paracortical hyperplasias, which may reflect a vigorous response to a viral infection, such as acute mononucleosis. The cells of paracortical hyperplasia may include a high proportion of large, rapidly dividing T immunoblasts that mimic the appearance of a lymphoma. Unlike PTCL, NOS, the T cells in benign hyperplasias have normal immunophenotypes and are typically polyclonal (by polymerase chain reaction [PCR]-based assays), and lack clonal T cell receptor (
         <em>
          TCR
         </em>
         ) rearrangements that are seen in PTCL, NOS. (See
         <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">
          "Infectious mononucleosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3838862785">
         <span class="h2">
          Granulomatous lymphadenitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some cases of PTCL, NOS generate a granulomatous host response in involved tissues, with granulomas that are so numerous that they overshadow the neoplastic lymphoid cells in the background. The most important distinguishing factor is careful morphologic inspection of the lymphoid cells, which usually shows significant cytologic atypia in PTCL, NOS. Difficult cases can be distinguished by immunophenotyping and PCR-based assays for
         <em>
          TCR
         </em>
         rearrangements, which reveal a polyclonal pattern in granulomatous lymphadenitis.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical course of PTCL, NOS is aggressive, and relapses are common [
         <a href="#rid6">
          6,11,57-60
         </a>
         ]. Disease stage at diagnosis and prognostic scoring systems correlate with survival in these patients  (
         <a class="graphic graphic_table graphicRef70850" href="/z/d/graphic/70850.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid61">
          61
         </a>
         ]. Stage for stage, compared with B cell non-Hodgkin lymphomas (NHL), patients with PTCL generally have a worse prognosis [
         <a href="#rid7">
          7,16,58,62
         </a>
         ].
        </p>
        <p>
         The International Prognostic Index (IPI) score and various T cell NHL-specific models have been applied to PTCL.
        </p>
        <p class="headingAnchor" id="H4222307707">
         <span class="h2">
          International Prognostic Index (IPI)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to the routine use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         for treatment of B cell NHL, a retrospective analysis compared the ability of the IPI  (
         <a class="graphic graphic_table graphicRef70850" href="/z/d/graphic/70850.html" rel="external">
          table 2
         </a>
         ) to predict outcomes in 288 patients with PTCL and 1595 patients with B cell NHL [
         <a href="#rid62">
          62
         </a>
         ]. Compared with B cell NHL, cases of PTCL had more disseminated disease, B symptoms, and involvement of bone marrow or skin, but less bulky disease.
        </p>
        <p>
         Patients with PTCL demonstrated [
         <a href="#rid62">
          62
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distribution of IPI scores
         </strong>
         – For all patients with PTCL, IPI scores of 0, 1, 2, and ≥3 were reported in 13, 17, 24, and 45 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Survival
         </strong>
         – Five-year overall survival (OS) for patients with PTCL varied with IPI score:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          IPI 0
         </strong>
         –
         <strong>
         </strong>
         82 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          IPI
         </strong>
         <strong>
          1
         </strong>
         – 73 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          IPI 2
         </strong>
         – 58 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          IPI
         </strong>
         <strong>
          ≥3
         </strong>
         – 35 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3316509812">
         <span class="h2">
          Other models
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other prognostic scoring system models have been proposed for T cell NHL, but they require further validation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognostic Index for PTCL, unspecified (PIT)
         </strong>
         – This model assigns one point for each of the following criteria  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid63">
          63
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age &gt;60 years
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased serum lactate dehydrogenase
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Eastern Cooperative Oncology Group (ECOG) performance status ≥2
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bone marrow involvement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A retrospective multicenter study of 385 patients with PTCL, NOS was used to develop the PIT prognostic score and it demonstrated an association between increased score and decreased survival [
         <a href="#rid63">
          63
         </a>
         ]. Patients with zero, one, two, or three to four of the adverse prognostic factors had five-year OS rates of 63, 53, 33, and 18 percent, respectively. A second retrospective analysis of a smaller population also found the PIT score to correlate with OS and progression-free survival [
         <a href="#rid64">
          64
         </a>
         ]. However, when applied to another cohort of 340 cases of PTCL, NOS, the PIT was not superior to the IPI for predicting survival [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          International peripheral T cell lymphoma Project score (IPTCLP)
         </strong>
         – The IPTCLP incorporates age (≤60 versus &gt;60), ECOG performance score (≤1 versus &gt;1), and platelet count (≤150K versus &gt;150K) to classify patients into four groups [
         <a href="#rid65">
          65
         </a>
         ]. When applied to 121 patients with PTCL, patients who had zero, one, two, or three risk factors demonstrated five-year OS rates of 58, 15, 5, and zero percent, respectively.
        </p>
        <p>
        </p>
        <p>
         Other models have suggested the following features as potential predictors of a poor response: Ki-67 positivity of ≥80 percent, Epstein-Barr virus positivity, the presence of systemic B symptoms, low albumin, mediastinal lymphadenopathy, the presence of a "proliferation signature", and the expression of
         <em>
          GATA3
         </em>
         or
         <em>
          GATA3
         </em>
         target genes [
         <a href="#rid22">
          22,42,43,64,66-69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3082783033">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">
          "Society guideline links: Lymphoma diagnosis and staging"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Peripheral T cell lymphoma (PTCL), not otherwise specified (NOS) is a heterogeneous group of predominantly nodal T cell lymphomas that generally present with lymphadenopathy, with or without extranodal involvement. PTCL must be distinguished from other specifically-defined subtypes of PTCL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – PTCL, NOS is the most common type of PTCL in Western countries, accounting for approximately one-third of cases. The incidence varies geographically, with the highest incidence found in Asia. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Most patients present with generalized lymphadenopathy, with or without extranodal disease. Systemic B symptoms are common, and some cases demonstrate blood eosinophilia, pruritus, and/or hemophagocytosis. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathologic features
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Histology
         </strong>
         – Microscopy usually demonstrates a non-specific mixture of small, intermediate, and large atypical lymphoid cells  (
         <a class="graphic graphic_picture graphicRef83591" href="/z/d/graphic/83591.html" rel="external">
          picture 2
         </a>
         ) that may be associated with reactive inflammatory cells. (See
         <a class="local">
          'Histology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunophenotype
         </strong>
         – Variable, but it must confirm the T cell origin of the tumor by expression of at least one pan-T cell antigen (ie, CD2, CD3, CD5, CD7). Many cases demonstrate an aberrant immunophenotype (eg, loss of a pan-T cell antigen; especially CD5 or CD7) and, rarely, may include expression of B cell antigens. (See
         <a class="local">
          'Immunophenotype'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Genetic features
         </strong>
         – Approximately 90 percent of cases demonstrate cytogenetic abnormalities, but none is specific for PTCL, NOS. Most cases have clonal T cell receptor (
         <em>
          TCR
         </em>
         ) gene rearrangements.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – PTCL, NOS and other lymphomas may be suspected in individuals with lymphadenopathy, splenomegaly, constitutional symptoms, and findings related to organ infiltration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Specimen
         </strong>
         – Diagnosis requires an adequate specimen (ideally, an excisional or incisional biopsy) that permits characterization of morphology and immunophenotype. (See
         <a class="local">
          'Biopsy specimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Criteria
         </strong>
         – PTCL, NOS is a diagnosis of exclusion, based on:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Morphology
         </strong>
         – Variable mixtures of atypical small, intermediate, and large lymphoid cells with pleomorphic, irregular, vesicular, or hyperchromatic nuclei with prominent nucleoli and a high mitotic rate. (See
         <a class="local">
          'Morphology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Immunophenotype
         </strong>
         – Variable, but one or more pan-T antigens (ie, CD2, CD3, CD5, CD7) must be expressed. (See
         <a class="local">
          'Immunophenotypic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Exclude other categories of PTCL
         </strong>
         – The tumor does not meet the criteria for other subtypes of T cell lymphoma  (
         <a class="graphic graphic_table graphicRef55385" href="/z/d/graphic/55385.html" rel="external">
          table 1
         </a>
         ), as described above. (See
         <a class="local">
          'Exclude other categories of PTCL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Genetic studies are not required to diagnose or further classify PTCL, NOS, except to exclude other diagnoses. Although chromosomal and molecular abnormalities are common, none is specific for the diagnosis of PTCL, NOS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of PTCL, NOS includes other T cell lymphomas, B cell lymphomas, and Hodgkin lymphomas and certain forms of reactive lymphoid hyperplasia, as discussed above. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The clinical course of PTCL, NOS is aggressive, and relapses are common. The International Prognostic Index (IPI)  (
         <a class="graphic graphic_table graphicRef70850" href="/z/d/graphic/70850.html" rel="external">
          table 2
         </a>
         ) and other scoring systems can be used to estimate prognosis for patients with PTCL. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medeiros LJ, Lardelli P, Stetler-Stevenson M, et al. Genotypic analysis of diffuse, mixed cell lymphomas. Comparison with morphologic and immunophenotypic findings. Am J Clin Pathol 1991; 95:547.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 2014; 25:2211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014; 124:1570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008; 49:2099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011; 117:3402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams SV, Newcomb PA, Shustov AR. Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. J Clin Oncol 2016; 34:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dogan A, Morice WG. Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol 2004; 127:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphomas of the intestine. Am J Pathol 1992; 141:1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez CL, Medeiros LJ, Braziel RM, Jaffe ES. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991; 15:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102:2213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood 1990; 75:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suchi T, Lennert K, Tu LY, et al. Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification. J Clin Pathol 1987; 40:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss LM, Crabtree GS, Rouse RV, Warnke RA. Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas. Am J Pathol 1985; 118:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patsouris E, Noël H, Lennert K. Histological and immunohistological findings in lymphoepithelioid cell lymphoma (Lennert's lymphoma). Am J Surg Pathol 1988; 12:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006; 24:2472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borowitz MJ, Reichert TA, Brynes RK, et al. The phenotypic diversity of peripheral T-cell lymphomas: the Southeastern Cancer Study Group experience. Hum Pathol 1986; 17:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahemtullah A, Longtine JA, Harris NL, et al. CD20+ T-cell lymphoma: clinicopathologic analysis of 9 cases and a review of the literature. Am J Surg Pathol 2008; 32:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003; 27:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boehm T, Baer R, Lavenir I, et al. The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor C delta locus on human chromosome 14q11 and a transcribed region of chromosome 11p15. EMBO J 1988; 7:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caccia N, Bruns GA, Kirsch IR, et al. T cell receptor alpha chain genes are located on chromosome 14 at 14q11-14q12 in humans. J Exp Med 1985; 161:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caccia N, Kronenberg M, Saxe D, et al. The T cell receptor beta chain genes are located on chromosome 6 in mice and chromosome 7 in humans. Cell 1984; 37:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hecht F, Morgan R, Hecht BK, Smith SD. Common region on chromosome 14 in T-cell leukemia and lymphoma. Science 1984; 226:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaneko Y, Maseki N, Homma C, et al. Chromosome translocations involving band 7q35 or 7p15 in childhood T-cell leukemia/lymphoma. Blood 1988; 72:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlegelberger B, Himmler A, Gödde E, et al. Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade and high-grade lymphomas. Blood 1994; 83:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ong ST, Le Beau MM. Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma. Semin Oncol 1998; 25:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss LM, Trela MJ, Cleary ML, et al. Frequent immunoglobulin and T-cell receptor gene rearrangements in "histiocytic" neoplasms. Am J Pathol 1985; 121:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss LM, Picker LJ, Grogan TM, et al. Absence of clonal beta and gamma T-cell receptor gene rearrangements in a subset of peripheral T-cell lymphomas. Am J Pathol 1988; 130:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann S, Gesk S, Scholtysik R, et al. High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus. Br J Haematol 2010; 148:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agostinelli C, Piccaluga PP, Went P, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol 2008; 61:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012; 120:2280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009; 23:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maura F, Dodero A, Carniti C, et al. CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Haematologica 2021; 106:2918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007; 117:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 2014; 123:3007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123:2915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood 2019; 133:1664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109:4952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccaluga PP, Fuligni F, De Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol 2013; 31:3019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watatani Y, Sato Y, Miyoshi H, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia 2019; 33:2867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hastrup N, Ralfkiaer E, Pallesen G. Aberrant phenotypes in peripheral T cell lymphomas. J Clin Pathol 1989; 42:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinkus GS, O'Hara CJ, Said JW. Peripheral/post-thymic T-cell lymphomas: a spectrum of disease. Clinical, pathologic, and immunologic features of 78 cases. Cancer 1990; 65:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amador C, Greiner TC, Heavican TB, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood 2019; 134:2159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Leval L, Gaulard P. Cellular origin of T-cell lymphomas. Blood 2014; 123:2909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolae A, Bouilly J, Lara D, et al. Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations. Mod Pathol 2022; 35:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014; 124:1473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry AM, Choi SM. Kikuchi-Fujimoto Disease: A Review. Arch Pathol Lab Med 2018; 142:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisenburger DD, Linder J, Armitage JO. Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases. Hematol Oncol 1987; 5:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990; 1:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armitage JO, Greer JP, Levine AM, et al. Peripheral T-cell lymphoma. Cancer 1989; 63:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lippman SM, Miller TP, Spier CM, et al. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood 1988; 72:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116:3418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103:2474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee Y, Uhm JE, Lee HY, et al. Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". Ann Hematol 2009; 88:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutiérrez-García G, García-Herrera A, Cardesa T, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 2011; 22:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006; 108:4163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chihara D, Oki Y, Ine S, et al. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 2009; 50:1999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuadros M, Dave SS, Jaffe ES, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007; 25:3321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valleron W, Ysebaert L, Berquet L, et al. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. Blood 2012; 120:3997.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4694 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9704731" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2014781" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Genotypic analysis of diffuse, mixed cell lymphomas. Comparison with morphologic and immunophenotypic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2014781" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genotypic analysis of diffuse, mixed cell lymphomas. Comparison with morphologic and immunophenotypic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9166827" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25193992" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25006130" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19021052" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18626005" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21270441" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26962200" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15461619" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Bone marrow histopathology in peripheral T-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1466400" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Peripheral T-cell lymphomas of the intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1985499" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12750155" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2153036" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Peripheral T-cell lymphoma associated with hemophagocytic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3312308" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3155915" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8068936" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2452579" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Histological and immunohistological findings in lymphoepithelioid cell lymphoma (Lennert's lymphoma).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16636342" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3011639" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The phenotypic diversity of peripheral T-cell lymphomas: the Southeastern Cancer Study Group experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18753947" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : CD20+ T-cell lymphoma: clinicopathologic analysis of 9 cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14657710" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Peripheral T-cell lymphomas expressing CD30 and CD15.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3259177" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor C delta locus on human chromosome 14q11 and a transcribed region of chromosome 11p15.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3872924" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : T cell receptor alpha chain genes are located on chromosome 14 at 14q11-14q12 in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6331676" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The T cell receptor beta chain genes are located on chromosome 6 in mice and chromosome 7 in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6438800" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Common region on chromosome 14 in T-cell leukemia and lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2900030" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Chromosome translocations involving band 7q35 or 7p15 in childhood T-cell leukemia/lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8286748" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade and high-grade lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9728595" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3907361" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Frequent immunoglobulin and T-cell receptor gene rearrangements in "histiocytic" neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3258126" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Absence of clonal beta and gamma T-cell receptor gene rearrangements in a subset of peripheral T-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19863542" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18755717" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19965671" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22855598" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18987657" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33054126" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17304354" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24497534" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24632715" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30782609" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17284527" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23857971" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24413734" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31092896" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2469701" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Aberrant phenotypes in peripheral T cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2297666" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Peripheral/post-thymic T-cell lymphomas: a spectrum of disease. Clinical, pathologic, and immunologic features of 78 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31562134" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24810625" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cellular origin of T-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35301414" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24894770" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30407860" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Kikuchi-Fujimoto Disease: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2888715" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1706610" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2783376" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Peripheral T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3261181" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660290" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9639502" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645001" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18648812" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20631009" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Comparison of four prognostic scores in peripheral T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16902151" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19860627" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17577022" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22990019" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
